b-u-i Review Blog

To be able to tell or rather foretell the client what might happen tomorrow insurance companies have to have certain expertise regarding the future. This is the methodology that they use in order to determine what would be the nature of the rates and the premium and what will be the nature of tomorrow so that an individual is actually able to afford this rates or premium.

As a result, the insurance industry wanted to be able to have access to information provided from genetic tests, as this would mean that people who had a genetic disposition towards certain serious illnesses could be accounted for, and pays higher premiums to protect the companies from the added risk of insuring such individuals.

The voluntary UK moratorium covers income protection policies up to the value of £30,000 per year, critical illness up to the value of £300,000, and life insurance of £500,000. It accounts for about 97% of insurance policies.

The ban on genetic information being passed to insurance companies is based on a theory that some health professionals hold that there are genetic markers for common serious diseases such as cancer and heart disease. Campaigners fear unfair discrimination such as increased premiums or a rejection of insurance if disclosure of genetic tests was granted, they argue that a positive test for a “disease” gene does not mean that illness is certain.

The ban is temporary, but really only temporary in name. It was first introduced in 2001 and campaigners had tried to have it extended beyond the initial expiry date of 2011. Their efforts were met with success and the ban will now stand until 2014 and will be reconsidered again in 2011.

Life insurers, however, have asked that they be allowed to have access to test results for diseases such as Huntingdon’s disease as people who test positive for the gene which causes Huntingdon’s are 100% likely to contract the illness. Insurers have only been granted the risk to ask for results of medical tests for the gene if the life insurance policy being taken out is worth more than £500,000.

Perhaps surprisingly to some the move has been welcomed by the ABI, the Association of British Insurers. “The moratorium on the use of predictive genetic test results works well for consumers,” said ABI director general Stephen Haddrill. “It means people can insure themselves and their families, even if they have had an adverse result from a predictive genetic test.”

The process involved in determining life insurance already involves estimating and calculating a wide number of variables. The involvement of genetic information would theoretically make this easier but critics have pointed out that there are very few cases in which it has been proved that a genetic disposition significantly enhances the likelihood of catching a certain disease. For the moment then, things will stay as they are and most people will remain on an even footing when it comes to trying to get a life insurance policy.

For more information please visit us at http://www.asdafinance.com/life-insurance.html

In order to state what might happen in the future, insurance companies have to be able to foretell the future, and that too with a fair amount of accuracy. In fact this is precisely how they formulate their premiums and rates, which they make looking forward to a certain future and determine what one may or may not be able to pay.

As a result, the insurance industries wanted to be able to have access to information provided from genetic tests, as this would mean that people who had a genetic disposition towards certain serious illnesses could be accounted for, and pay higher premiums to protect the companies from the added risk of insuring such individuals.

The ban is temporary, but really only temporary in name. It was first introduced in 2001 and campaigners had tried to have it extended beyond the initial expiry date of 2011. Their efforts were met with success and the ban will now stand until 2014 and will be reconsidered again in 2011.

Life insurers, however, have asked that they be allowed to have access to test results for diseases such as Huntingdon’s disease as people who test positive for the gene which causes Huntingdon’s are 100% likely to contract the illness. Insurers have only been granted the risk to ask for results of medical tests for the gene if the life insurance policy being taken out is worth more than £500,000.

Perhaps surprisingly to some the move has been welcomed by the ABI, the Association of British Insurers. “The moratorium on the use of predictive genetic test results works well for consumers,” said ABI director general Stephen Haddrill. “It means people can insure themselves and their families, even if they have had an adverse result from a predictive genetic test.”

The voluntary UK moratorium covers income protection policies up to the value of £30,000 per year, critical illness up to the value of £300,000, and life insurance of £500,000. It accounts for about 97% of insurance policies.

The ban on genetic information being passed to insurance companies is based on a theory that some health professionals hold that there are genetic markers for common serious diseases such as cancer and heart disease. Campaigners fear unfair discrimination such as increased premiums or a rejection of insurance if disclosure of genetic tests was granted, they argue that a positive test for a “disease” gene does not mean that illness is certain.

The process involved in determining life insurance already involves estimating and calculating a wide number of variables. The involvement of genetic information would theoretically make this easier but critics have pointed out that there are very few cases in which it has been proved that a genetic disposition significantly enhances the likelihood of catching a certain disease. For the moment then, things will stay as they are and most people will remain on an even footing when it comes to trying to get a life insurance policy.

For more information please visit us at http://www.asdafinance.com/life-insurance.html

To a certain degree insurance companies have to be able to look into the future and state what will happen with some sort of accuracy. Essentially, it is how they work out their rates and premiums. They need to look into the foreseeable future to see what they may or may not have to pay out.

As a result, the insurance industry wanted to be able to have access to information provided from genetic tests, as this would mean that people who had a genetic disposition towards certain serious illnesses could be accounted for, and pay higher premiums to protect the companies from the added risk of insuring such individuals.

The ban is temporary, but really only temporary in name. It was first introduced in 2001 and campaigners had tried to have it extended beyond the initial expiry date of 2011. Their efforts were met with success and the ban will now stand until 2014 and will be reconsidered again in 2011.

The voluntary UK moratorium covers income protection policies up to the value of £30,000 per year, critical illness up to the value of £300,000, and life insurance of £500,000. It accounts for about 97% of insurance policies.

The ban on genetic information being passed to insurance companies is based on a theory that some health professionals hold that there are genetic markers for common serious diseases such as cancer and heart disease. Campaigners fear unfair discrimination such as increased premiums or a rejection of insurance if disclosure of genetic tests was granted, they argue that a positive test for a “disease” gene does not mean that illness is certain.

Life insurers, however, have asked that they be allowed to have access to test results for diseases such as Huntingdon’s disease as people who test positive for the gene which causes Huntingdon’s are 100% likely to contract the illness. Insurers have only been granted the risk to ask for results of medical tests for the gene if the life insurance policy being taken out is worth more than £500,000.

Perhaps surprisingly to some the move has been welcomed by the ABI, the Association of British Insurers. “The moratorium on the use of predictive genetic test results works well for consumers,” said ABI director general Stephen Haddrill. “It means people can insure themselves and their families, even if they have had an adverse result from a predictive genetic test.”

The process involved in determining life insurance already involves estimating and calculating a wide number of variables. The involvement of genetic information would theoretically make this easier but critics have pointed out that there are very few cases in which it has been proved that a genetic disposition significantly enhances the likelihood of catching a certain disease. For the moment then, things will stay as they are and most people will remain on an even footing when it comes to trying to get a life insurance policy.

For more information please visit us at http://www.asdafinance.com/life-insurance.html